Q3 EPS Forecast for Oric Pharmaceuticals Reduced by Analyst

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for shares of Oric Pharmaceuticals in a report issued on Monday, August 10th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.40) for the quarter, down from their prior forecast of ($0.36). HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Oric Pharmaceuticals’ current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Oric Pharmaceuticals’ Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.54) EPS, Q3 2027 earnings at ($0.47) EPS and Q4 2027 earnings at ($0.49) EPS.

ORIC has been the topic of a number of other reports. Wall Street Zen raised Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. Benchmark restated a “buy” rating on shares of Oric Pharmaceuticals in a research report on Monday, June 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. Citigroup cut their target price on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Friday, July 17th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.45.

Oric Pharmaceuticals Stock Up 0.8%

NASDAQ:ORIC opened at $13.73 on Wednesday. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -10.17 and a beta of 1.02. Oric Pharmaceuticals has a 52 week low of $7.23 and a 52 week high of $14.93. The company’s 50 day moving average price is $10.36 and its 200-day moving average price is $10.48.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.02).

Institutional Trading of Oric Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ORIC. Federation des caisses Desjardins du Quebec increased its holdings in Oric Pharmaceuticals by 100.0% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after buying an additional 2,000 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Oric Pharmaceuticals by 184.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock worth $37,000 after acquiring an additional 2,936 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Oric Pharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after acquiring an additional 977 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Oric Pharmaceuticals in the 3rd quarter worth $60,000. Finally, CANADA LIFE ASSURANCE Co bought a new position in Oric Pharmaceuticals in the 3rd quarter worth $65,000. 95.05% of the stock is currently owned by institutional investors.

Trending Headlines about Oric Pharmaceuticals

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $27 target price for Oric Pharmaceuticals (ORIC), providing a favorable valuation signal for investors. HC Wainwright analyst estimates and rating
• Neutral Sentiment: HC Wainwright projected continued quarterly losses, including EPS of $(0.43) in Q1 2027, $(0.45) in Q2 2027, $(0.47) in Q3 2027 and $(0.49) in Q4 2027, implying a full-year 2027 loss of $(1.85). The estimates reflect continued research and development spending rather than near-term profitability. Oric Pharmaceuticals 2027 EPS estimates
• Negative Sentiment: HC Wainwright reduced its forecasts for Q3 2026 EPS to $(0.40) from $(0.36), Q4 2026 EPS to $(0.42) from $(0.37), and FY2026 EPS to $(1.54) from $(1.41). These revisions point to somewhat higher expected losses and may limit near-term upside, although the estimates remain close to the broader full-year consensus of $(1.51). Oric Pharmaceuticals 2026 EPS estimate revisions
• Neutral Sentiment: Reported short interest was listed at zero shares with zero days to cover, but the data appears inconsistent and offers little actionable information about trading pressure.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.